General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded without agreement
Manufacturer:
KYE Pharmaceuticals Inc.
Indication:
Angina Pectoris
Last updated January 23, 2023
Status:
Concluded with an LOI
Manufacturer:
Knight Therapeutics Inc.
Indication:
Postmenopausal dyspareunia, moderate to severe
Last updated January 20, 2023
Status:
Concluded with an LOI
Manufacturer:
Medexus Pharmaceuticals, Inc.
Indication:
Pediatric chronic severe drooling reduction (neurologic)
Last updated January 16, 2023
Status:
Concluded with an LOI
Manufacturer:
Valeo Pharma Inc.
Indication:
Parkinson's disease
Last updated January 16, 2023
Elonox and Elonox HP (enoxaparin sodium)
Status:
Concluded with an LOI
Manufacturer:
Fresenius Kabi Canada Ltd.
Indication:
Thrombosis and cardiovascular conditions (prevention or treatment)
Last updated January 9, 2023
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Urothelial carcinoma (UC), monotherapy for the adjuvant treatment of adult patients who are at high risk of recurrence after undergoing radical resection of UC
Last updated December 23, 2022
Status:
Concluded without agreement
Manufacturer:
Merz Therapeutics Canada
Indication:
Chronic Sialorrhea associated with neurological disorders
Last updated December 23, 2022
Status:
Concluded with an LOI
Manufacturer:
BeiGene, Ltd.
Indication:
Waldenström's Macroglobulinemia
Last updated December 22, 2022
Status:
Concluded without agreement
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated December 20, 2022
Status:
Negotiations were not pursued
Manufacturer:
AbbVie Corporation
Indication:
Bipolar Disorder
Last updated December 16, 2022